Norway Savings Bank lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 9.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,801 shares of the biopharmaceutical company’s stock after purchasing an additional 2,490 shares during the period. Norway Savings Bank’s holdings in Pfizer were worth $1,020,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of PFE. Corbett Road Capital Management LLC acquired a new stake in Pfizer during the 2nd quarter valued at $25,000. Reitz Capital Advisors LLC acquired a new position in shares of Pfizer in the second quarter worth $29,000. Rocky Mountain Advisers LLC lifted its position in shares of Pfizer by 847.5% in the second quarter. Rocky Mountain Advisers LLC now owns 1,118 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 1,000 shares in the last quarter. Disciplined Investments LLC boosted its stake in shares of Pfizer by 43.3% during the first quarter. Disciplined Investments LLC now owns 1,148 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 347 shares during the last quarter. Finally, JJJ Advisors Inc. acquired a new stake in shares of Pfizer during the second quarter valued at $44,000. Hedge funds and other institutional investors own 69.08% of the company’s stock.

In other Pfizer news, Director Ronald E. Blaylock purchased 13,000 shares of the business’s stock in a transaction that occurred on Thursday, August 6th. The shares were purchased at an average price of $38.55 per share, for a total transaction of $501,150.00. Following the completion of the acquisition, the director now owns 4,000 shares of the company’s stock, valued at approximately $154,200. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.08% of the stock is currently owned by corporate insiders.

PFE stock opened at $37.95 on Friday. The company has a quick ratio of 1.16, a current ratio of 1.42 and a debt-to-equity ratio of 0.78. The company has a market cap of $210.88 billion, a price-to-earnings ratio of 15.06, a PEG ratio of 2.91 and a beta of 0.67. The business has a fifty day simple moving average of $36.59 and a 200-day simple moving average of $36.32. Pfizer Inc. has a 52 week low of $27.88 and a 52 week high of $40.97.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, July 28th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.64 by $0.14. The firm had revenue of $11.80 billion during the quarter, compared to the consensus estimate of $11.55 billion. Pfizer had a return on equity of 25.11% and a net margin of 28.80%. The firm’s quarterly revenue was down 11.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.80 earnings per share. As a group, analysts expect that Pfizer Inc. will post 2.89 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 1st. Stockholders of record on Friday, November 6th will be issued a dividend of $0.38 per share. This represents a $1.52 dividend on an annualized basis and a dividend yield of 4.01%. The ex-dividend date of this dividend is Thursday, November 5th. Pfizer’s payout ratio is currently 51.53%.

A number of research analysts have issued reports on PFE shares. Mizuho restated a “buy” rating and issued a $43.00 target price on shares of Pfizer in a report on Tuesday, September 15th. UBS Group upped their price objective on shares of Pfizer from $37.00 to $39.00 and gave the company a “neutral” rating in a research note on Wednesday, July 29th. Royal Bank of Canada set a $43.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research note on Friday. Morgan Stanley boosted their price target on Pfizer from $36.00 to $42.00 and gave the company an “equal weight” rating in a report on Thursday, July 30th. Finally, Atlantic Securities cut Pfizer from an “overweight” rating to a “neutral” rating and decreased their price objective for the stock from $44.00 to $39.00 in a report on Monday, October 12th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $39.64.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Article: How to invest using market indexes

Want to see what other hedge funds are holding PFE? Visit to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with's FREE daily email newsletter.